2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-152150
    Thrombin inhibitor 7 2866508-00-9 98%
    Thrombin inhibitor 7 is a potent FXIIa inhibitor with IC50 values of 28 nM, >132 µM for FXIIa and FXIa, respectively. Thrombin inhibitor 7 shows low cytotoxicity.
    Thrombin inhibitor 7
  • HY-152158
    α-Glucosidase-IN-22 2870693-28-8 99.13%
    α-Glucosidase-IN-22 (Compound 7i) is a α-glucosidase inhibitor with an IC50 value of 0.64 μM. α-Glucosidase-IN-22 can be used for the research of type 2 diabetes.
    α-Glucosidase-IN-22
  • HY-152199
    AMPD2 inhibitor 2 3026893-31-9 98%
    AMPD2 inhibitor 2 (compound 21) is a potent AMP deaminase 2 (AMPD2) inhibitor with IC50s of 0.1 μM and 0.28μM for hAMPD2 and mAMPD2, respectively. AMPD2 inhibitor 2 has the potential for evaluating the physiological role of AMPD2 in mice maintained on a high fat diet.
    AMPD2 inhibitor 2
  • HY-152953
    (R)-Lactoyl-CoA 4625-32-5 98%
    (R)-Lactoyl-CoA ((R)-Lactoyl-coenzyme A) is a lactoyl-CoA in which the lactoyl residue has (R)-configuration.
    (R)-Lactoyl-CoA
  • HY-153010
    ER proteostasis regulator-1 912777-95-8 ≥98.0%
    ER proteostasis regulator-1 (compound 481) is a potent ER proteostasis regulator. ER proteostasis regulator-1 has the potential for the research of Alzheimer's disease and diabetes.
    ER proteostasis regulator-1
  • HY-153057
    PRMT5-IN-46 380192-76-7 98%
    PRMT5-IN-46 (compound 278) inhibits PRMT5 with IC50s of 1-10 μM. PRMT5 is a methyltransferase which is associated with specific genetic alterations. PRMT5-IN-46 can be used for research of proliferative diseases, metabolic disorders, and blood diseases.
    PRMT5-IN-46
  • HY-153095
    PF-6870961 2857112-06-0 98%
    PF-6870961 is an inverse agonist of GHSR1a with Ki values of 73.6 nM (human GHSR), 239 nM (rat GHSR), and 217 nM (dog GHSR), respectively. PF-6870961 inhibits the constitutive GHSR1a-induced IP accumulation with an IC50 value of 300 nM. PF-6870961 also inhibits constitutive GHSR1a β-arrestin mobilization with an IC50 value of 1.10 nM.
    PF-6870961
  • HY-153149
    LJ-2698 945457-84-1 98%
    LJ-2698 (FM101) is an orally active adenosine A3 receptor (Adenosine A3 Receptor) antagonist. LJ-2698 blocks adenosine A3 receptor-dependent pro-inflammatory JNK, ERK, and NF-κB signaling pathways. LJ-2698 prevents alveolar cavity enlargement, restores pulmonary function, and inhibits matrix metalloproteinase activity and pulmonary cell apoptosis (apoptosis) in mice. LJ-2698 induces mitochondrial dysfunction, necroptosis, and intrinsic apoptosis. LJ-2698 ameliorates renal injury in mice with diabetic nephropathy, and alleviates diet-induced hepatic inflammation and fibrosis. LJ-2698 can be used in the research of emphysema, diabetic nephropathy, and metabolic dysfunction-associated steatotic liver disease.
    LJ-2698
  • HY-153184
    GalNAc-L96 free base 1159408-61-3 98%
    GalNAc-L96 free base is a conjugate of GalNAc and its ligand L96. When conjugated with the A-rich HCV sequence (H12), GalNAc-L96 free base binds potently to ASGPR, with a Ki value of 10.4 nM. GalNAc-L96 free base promotes siRNA delivery to hepatocytes.
    GalNAc-L96 free base
  • HY-153256
    EP3 antagonist 4 2408297-80-1 98%
    EP3 antagonist 4 (Compound 28) is an EP3 antagonist, with a Ki value of 2 nM for hEP. EP3 antagonist 4 shows low in vivo clearance, high oral AUC, and good bioavailability in the rat full PK studies. EP3 antagonist 4 can be used for research of beta cell dysfunction in diabetes.
    EP3 antagonist 4
  • HY-153258
    CaSR antagonist-1 1219811-83-2 98%
    CaSR antagonist-1 is a calcium sensing receptor (CaSR) antagonist with an IC50 value of 50 nM. CaSR antagonist-1 can be used for the research of disorders associated with abnormal bone or mineral homeostasis such as osteoporosis.
    CaSR antagonist-1
  • HY-153354
    PKR activator 4 2283420-05-1
    PKR activator 4 (example 7A) is a potent pyruvate kinase R (PKR) activator. PKR activator 4 has the potential for the research of blood disorders.
    PKR activator 4
  • HY-153391
    PCSK9-IN-14 2913198-84-0 98%
    PCSK9-IN-14 (compound Ia-8) is a potent PCSK9 inhibitor.
    PCSK9-IN-14
  • HY-153451
    PCSK9-IN-15 2455423-94-4 98%
    PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia.
    PCSK9-IN-15
  • HY-153454
    PCSK9-IN-18 2455425-15-5 98%
    PCSK9-IN-18 (compound 188) is a potent PCSK9 inhibitor with a KD value of <200 nM.
    PCSK9-IN-18
  • HY-153455
    TRPC3/6-IN-2 2387893-55-0 98%
    TRPC3/6-IN-2 is a potent TRPC3/6 inhibitor with IC50 values of 16 nM and 29.8 nM for TRPC3 and TRPC6, respectively.
    TRPC3/6-IN-2
  • HY-153458
    Orexin receptor modulator-1 2125735-57-9 98%
    Orexin receptor modulator-1 is an orexin receptor modulator. Orexin receptor modulator-1 can be used for the research of substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Orexin receptor modulator-1
  • HY-153493
    PF-04523655 1420046-64-5
    PF-04523655 is a siRNA directed against RTP801 gene. RTP801 is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.
    PF-04523655
  • HY-153507
    DGAT1-IN-4 1137671-16-9 98%
    DGAT1-IN-4 is a potent, orally active, and selective DGAT1 inhibitor with an IC50 of 17 nM. DGAT1-IN-4 exhibits >588-fold selectivity over DGAT2. DGAT1-IN-4 suppresses intracellular triglyceride synthesis in mouse myoblast cells. DGAT1-IN-4 suppresses body weight gain in diet-induced obese dogs. DGAT1-IN-4 can be used for the research of obesity.
    DGAT1-IN-4
  • HY-153522
    ZY15557 1601480-12-9 98%
    ZY15557 is a novel, competitive, long acting, orally active DPP-4 inhibitor, with a Ki of 5.53 nM. ZY15557 inhibits plasma DPP-4 activity. ZY15557 can be used in the research of type 2 diabetes.
    ZY15557
Cat. No. Product Name / Synonyms Application Reactivity